Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Geoffrey Y Ku

Showing results (91-100 of 104) with videos related to

Pageof 11
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 29, 2025
Clinical Implications of The Cancer Genome Atlas Molecular Classification System in Esophagogastric CancerHenry S Walch, Raktim Borpatragohain, Justin Jee, et al.
The Oncologist|October 2, 2019
Regorafenib in Combination with First-Line Chemotherapy for Metastatic Esophagogastric CancerRyan H Moy, Gustavo Dos Santos Fernandes, Philip Jonsson, et al.
Journal of the National Cancer Institute|September 12, 2023
Clinical and molecular characteristics of early-onset vs average-onset esophagogastric cancerMelissa A Lumish, Henry Walch, Steven B Maron, et al.
JAMA Network Open|February 2, 2023
Clinical Importance of Clonal Hematopoiesis in Metastatic Gastrointestinal Tract CancersBill H Diplas, Ryan Ptashkin, Joanne F Chou, et al.
JAMA Network Open|July 12, 2021
Prevalence of Germline Alterations on Targeted Tumor-Normal Sequencing of Esophagogastric CancerGeoffrey Y Ku, Yelena Kemel, Steve B Maron, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 3, 2019
Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction AdenocarcinomaRonan J Kelly, Jeeyun Lee, Yung-Jue Bang, et al.
Cancer|August 5, 2021
Pancreas cancer and BRCA: A critical subset of patients with improving therapeutic outcomesParisa Momtaz, Catherine A O'Connor, Joanne F Chou, et al.
The Lancet. Oncology|May 22, 2020
First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trialYelena Y Janjigian, Steven B Maron, Walid K Chatila, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2022
Epidermal Growth Factor Receptor Inhibition in Epidermal Growth Factor Receptor-Amplified Gastroesophageal Cancer: Retrospective Global ExperienceSteven B Maron, Stephanie Moya, Federica Morano, et al.
JCO Precision Oncology|April 22, 2026
Targeted Molecular Profiling of Circulating Cell-Free DNA in Patients With Gastroesophageal AdenocarcinomaSamuel L Cytryn, Raktim Borpatragohain, Karmelina Charalambous, et al.
Pageof 11

Showing results (91-100 of 104) with videos related to

Sort By:
Pageof 11
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 29, 2025
Clinical Implications of The Cancer Genome Atlas Molecular Classification System in Esophagogastric CancerHenry S Walch, Raktim Borpatragohain, Justin Jee, et al.
The Oncologist|October 2, 2019
Regorafenib in Combination with First-Line Chemotherapy for Metastatic Esophagogastric CancerRyan H Moy, Gustavo Dos Santos Fernandes, Philip Jonsson, et al.
Journal of the National Cancer Institute|September 12, 2023
Clinical and molecular characteristics of early-onset vs average-onset esophagogastric cancerMelissa A Lumish, Henry Walch, Steven B Maron, et al.
JAMA Network Open|February 2, 2023
Clinical Importance of Clonal Hematopoiesis in Metastatic Gastrointestinal Tract CancersBill H Diplas, Ryan Ptashkin, Joanne F Chou, et al.
JAMA Network Open|July 12, 2021
Prevalence of Germline Alterations on Targeted Tumor-Normal Sequencing of Esophagogastric CancerGeoffrey Y Ku, Yelena Kemel, Steve B Maron, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 3, 2019
Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction AdenocarcinomaRonan J Kelly, Jeeyun Lee, Yung-Jue Bang, et al.
Cancer|August 5, 2021
Pancreas cancer and BRCA: A critical subset of patients with improving therapeutic outcomesParisa Momtaz, Catherine A O'Connor, Joanne F Chou, et al.
The Lancet. Oncology|May 22, 2020
First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trialYelena Y Janjigian, Steven B Maron, Walid K Chatila, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2022
Epidermal Growth Factor Receptor Inhibition in Epidermal Growth Factor Receptor-Amplified Gastroesophageal Cancer: Retrospective Global ExperienceSteven B Maron, Stephanie Moya, Federica Morano, et al.
JCO Precision Oncology|April 22, 2026
Targeted Molecular Profiling of Circulating Cell-Free DNA in Patients With Gastroesophageal AdenocarcinomaSamuel L Cytryn, Raktim Borpatragohain, Karmelina Charalambous, et al.
Pageof 11